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HIV-1 subtype C is the most common HIV-1 group M subtype in Africa and many parts of Asia. However, to date HIV-1 vaccine candidate
immunogens have not induced potent and broadly neutralizing antibodies against subtype C primary isolates. We have used a centralized gene
strategy to address HIV-1 diversity and generated a group M consensus envelope gene with shortened consensus variable loops (CON-S) for
comparative studies with wild-type (WT) Env immunogens. Our results indicate that the consensus HIV-1 group M CON-S Env elicited cross-
subtype neutralizing antibodies of similar or greater breadth and titer than the WT Envs tested, indicating the utility of a centralized gene strategy.
Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes.
© 2006 Published by Elsevier Inc.Keywords: HIV-1; Vaccine; Neutralization antibody; Consensus immunogensIntroduction
Design of an immunogen that can induce broadly reactive
neutralizing antibodies against HIV-1 primary isolates is a
major goal of HIV-1 vaccine development. To address the
problem of HIV-1 diversity for antibody induction, we have
begun to design, synthesize, and test group M consensus
envelope genes as centralized immunogens using a variety of
different vector systems. The first generation group M
consensus env gene, termed CON6, was derived from the
1999 Los Alamos HIV env Sequence Database. CON6 env
encoded an Env protein that was biologically functional but⁎ Corresponding author.
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doi:10.1016/j.virol.2006.04.043contained the variable loops of a contemporary subtype C
isolate (Gao et al., 2005). CON-6 Env mediated infection of
CD4/CCR5-positive target cells with reduced efficiency
compared to wild-type (WT) Env and induced cross-subtype
T cell responses in mice (Gao et al., 2005). However, the
neutralizing antibody responses induced by CON6 Env were
limited to only a subset of subtype B HIV-1 primary isolates
(Gao et al., 2005).
Several studies have indicated that mutations or deletions of
variable loops in the envelope glycoproteins of HIV-1 and
simian immunodeficiency virus (SIV) may increase the number
and/or exposure of available neutralization epitopes within the
virion-associated viral envelope (Kang et al., 2005; Gzyl et al.,
2004; Yang et al., 2004; Kim et al., 2003; Barnett et al., 2001;
Wyatt et al., 1993). Our second generation group M consensus
Fig. 1. Infectivity and co-receptor usage of CON-S gp160-pseudotyped virus.
(A) Infectivity in TZM-bl cells. Virus stocks were generated in 293T cells by co-
transfection of consensus (CON6 and CON-S) and wild-type Envs (NL4-3, YU-
2) with the HIV-1/SG3Δenv backbone (No Env). Infectivity was determined by
counting the number of blue cells (infectious units, IU) per microgram of p24 of
pseudovirion stock (IU/μg p24) after staining the infected cells for β-
galactosidase expression. Bars indicate standard errors (values are averaged
from three independent experiments). (B) Co-receptor usage of CON-S Env
(gp160) containing pseudovirions. TZM-bl (JC53-BL) cells were pretreated
with ADM3100 (CXCR4 inhibitor), TAK-779 (CCR5 inhibitor), both or neither
(media) before being infected with CON6, CON-S, NL4-3, and YU-2 Env
containing pseudovirions.
Fig. 2. SDS–PAGE and blue native gel analysis of HIV-1 envelope proteins.
Panel A shows the results of SDS–PAGE analysis of HIV-1 B.6101 and B.BaL
gp120 proteins. HIV-1 gp120 proteins, as indicated on the top of the gel, were
fractionated on 4–20% gradient SDS–PAGE under reducing conditions and
stained by Coomassie blue. Panel B shows the results of blue native gel analysis
of HIV-1 Env gp140 proteins with HIV-1 gp140 proteins indicated on the top of
the 3–8% polyacrylamide gels and protein bands of molecular weight markers
of 669 (Thyroglobulin), 440 (ferritin), 232 (catalase), 140 (lactate dehydroge-
nase), and 66 (albumin) kDa indicated on the right hand side of the gel.
Arrowheads indicate HIV-1 protein forms (Panel B). Panel C shows SDS–
PAGE analysis of the uncleaved HXB2 gp120 Env as a control versus
A.92RW020 gp140ΔCF that is approximately 40% cleaved. Gel shows the
results of HXB2 gp120 and A.92RW020 gp140ΔCF analyzed under reducing
conditions in SDS–PAGE followed by Coomassie blue staining. In this gel,
96 kDa band of A.92RW020 Env represents approximately 40% of this
preparation. Analysis of 3 separate lots of purified A.92RW020 Env revealed the
96-kDa fragment to be 39 ± 13% of the Env protein preparation.
269H.-X. Liao et al. / Virology 353 (2006) 268–282env gene, termed CON-S, is not only based on a more
comprehensive collection of HIV-1 env sequences from the
2001 Los Alamos HIV-1 sequence database but also contains
minimal lengths of consensus rather than wild-type variable
loop sequences. In this paper, we describe the biological
properties of the CON-S Env glycoprotein and compare its
ability to induce neutralizing antibodies with that of CON6 and
five WT Env glycoproteins.
Results
Infectivity and co-receptor usage of the CON-S envelope
glycoprotein
We previously demonstrated that the CON6 Env (which
contains Group M consensus core regions but contemporary
subtype C variable loops) was capable of mediating virus entry
into CD4 and CCR5 bearing target cells (Gao et al., 2005) when
tested as a full-length (gp160) envelope in the form of
pseudovirions. Using this same approach, we determined the
infectivity profile and co-receptor usage of the CON-S Env
glycoprotein. CON-S gp160 conferred infectivity to HIV-1/
270 H.-X. Liao et al. / Virology 353 (2006) 268–282SG3Δenv in TZM-bl cells utilizing the CCR5 (but not the
CXCR4) co-receptor (Fig. 1A). However, compared to WT
HIV-1 envelopes (NL4-3 and YU-2), its infectivity was reduced
by two orders of magnitude. Consistent with previous
observations, CON6 gp160 analyzed in parallel yielded a
similar infectivity profile (Fig. 1A). Thus, “centralization”
seems to confer some functional impairment, at least in the
contextof thegroupMconsensusenvelopeglycoproteins.Fig.1B
shows that both CON6 and CON-S Env require CCR5 and not
CXCR4 for co-receptor.
We also characterized the neutralization phenotype of both
CON6 and CON-S pseudoviruses with sCD4, MAbs, serum,
and plasma pools from HIV-1-infected patients (Li et al.,
2005). We found that both CON6 and CON-S were sensitive to
sCD4 neutralization (both ∼12.0 μg/ml ID50) and to MAbs
IgG1b12, 2F5, and 4E10 (ID50 range for MAbs for both
viruses, 2.9–0.5 μg/ml). The analysis of the rank order of the
neutralization sensitivity showed that CON-S has a similar
sensitivity with B.SS1196.1 and was slightly more sensitive
than CON6 to neutralization by plasma and serum pools from
HIV-1-infected patients (Li et al., 2005). Both viruses wereFig. 3. Analysis of antigenic epitopes expressed on CON-S gp140ΔCFI by surface p
described in Materials and methods. Panel A shows the ability of CON-S gp140ΔCF
covalently immobilized to a CM5 sensor chip (BIAcore), and CON-S gp140ÄCFI w
induction of 17b MAb binding to CON-S gp140ΔCFI, we captured CON-S gp140Δ
sCD4 or MAb A32 or T8. Following stabilization of each of the surfaces, MAb 17b w
determine binding of CON-S gp140ΔCFI protein to human HIV-1 MAbs, we capture
immobilized with MAb T8. Following stabilization of each of the surfaces, the indicat
flow over each of the immobilized flow cells (C). Each analysis was performed at l∼20× less sensitive than the TCLA virus SF162 and MN (Li et
al., 2005).
Expression and characterization of Env gp120 monomers and
gp140 oligomers
To test the group M consensus andWTHIV-1 subtypes A, B,
and C Env glycoproteins as immunogens, we expressed
secreted versions (gp140) as ΔCFI with deletions of the
cleavage site, fusion domain, and immunodominant region
(CON-S, CON6, A.92RW020, C.97ZA012) or ΔCF with
deletions of the cleavage site and fusion domain (CON6, B.
JRFL) constructs in recombinant vaccinia virus (rVV) and
purified by lectin column chromatography. The ΔCFI or ΔCF
forms of the protein were used for these experiments because of
their improved immunogenicity and ability to assemble into
trimers (Chakrabarti et al., 2002). Two HIV-1 gp120 proteins,
B.6101 and B.BaL, were used as controls. Fig. 2A shows an
SDS–PAGE analysis of the two gp120 proteins, whereas Fig.
2B depicts a BN-PAGE of CON-S gp140ΔCFI, CON6
gp140ΔCF, and CON6 gp140ΔCFI as well as WT HIV-1lasmon resonance assays. Surface plasmon resonance assays were performed as
I to bind to sCD4, MAbs A32, and T8. sCD4 or HIV-1 MAbs T8 and A32 were
as injected over each surface (100 and 300 μg/ml, respectively). To determine
CFI protein (400–580 response units) on individual flow cells immobilized with
as injected and allowed to flow over each of the immobilized flow cells (B). To
d CON-S gp140ΔCFI protein (400–580 response units) on individual flow cells
ed humanMAb 7B2, 2G12, 4E10b, or irrelevant control MAb P3 was injected to
east twice.
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as monomers, whereas CON-S and CON6 gp140ΔCFI Envs
migrated as dimers, trimers, and tetramers (Gao et al., 2005). B.
JRFL gp140ΔCF protein migrated as monomers, dimers, and
trimers, whereas C.97ZA012 gp140ΔCFI migrated predomi-
nantly as trimers. The A.92RW020 gp140ΔCFI protein
preparation contained monomers, dimers, and approximately
40% cleaved Env products in spite of our efforts to eliminate
enzymatic degradation of Env during the protein purification
process. Fig. 2C shows Coomassie-strained SDS–PAGE gel
under reducing conditions. Approximately 40% of the
A.92RW020 Env is cleaved resulting in a 96-kDa fragment,
a pattern compatible with cleavage of gp120 near the V3 loop
(Schulz et al., 1993). Analysis of A.92RW020 gp140CF Env
after rVV expression and prior to Env purification demon-
strated identical results (not shown). Thus, partial cleavage of
A.92RW020 Env gp120 is a property of this particular Env
when expressed in 293T cells.
To compare antigenic and functional epitopes expressed on
the CON-S gp140ΔCFI protein with those expressed on
CON6 gp140 and other WT HIV-1 gp120 and gp140ΔCF/
CFI proteins, we assayed Envs for their ability to bind sCD4,
as well as well-characterized anti-HIV-1 gp120 and gp41anti-
bodies (Fig. 3, Table 1). We found that CON-S gp140ΔCFI
bound sCD4 and also bound human MAbs A32, 4E10, 2G12,
2F5, and mouse MAb T8 that recognizes the COOH-terminal
region of HIV-1 gp120 (Table 1). To determine whether the
CD4i MAb 17b that binds to the CCR5 binding site could be
induced on the purified CON-S gp140ΔCFI Env, we applied
either sCD4, MAb A32, or MAb T8 to a sensor chip to
capture CON-S gp140ΔCFI, and then MAb 17b bindingTable 1
Characterization of antigenic epitopes expressed on recombinant HIV-1 Env immun
Antigens CON6
gp140ΔCF
CON6
gp140ΔCFI
CON-S
gp140ΔCFI
CD4
sCD4 +* +* +*
1b12 ++ ++ ++
V3 loop epitopes
19b ++ ++ ++
F2A3 − + −
39F ++ ++ ++
CCR5 binding site(MAb 17b)
Constitutive − − −
CD4 induced + + +
A32 induced + + +
Other epitopes
2G12 +++ +++ +++
2F5 + +
4E10 ++ + +
A32 +* +* +*
* For binding of Mab A32 or sCD4 to ENVs, + = specific binding. Binding was ass
surfaces. About 150–200 responding units (RU) of specific binding were observed
Binding of Env proteins to all other MAbs were normalized by calculating binding
sensor surface. Binding ratio = binding of MAbs over binding of ENVs to A32 or T8 i
− = no specific binding.activity was determined. CON-S gp140CΔFI Env was
induced to bind MAb 17b only following binding to either
sCD4 or MAb A32, but not following binding to MAb T8
(Fig. 3B). The results of characterization of antigenic epitopes
expressed on the various recombinant HIV-1 Env glycopro-
teins using surface plasmon resonance analysis are summa-
rized in Table 1. All recombinant Envs bound to sCD4 and
MAb A32. Most of the Envs expressed epitopes recognized
by V3-specific antibodies, CD4-inducible antibodies, and
other epitopes recognized by MAb 2G12, 2F5, and 4E10
(Table 1). Whereas the protein preparations are heterogeneous,
these studies provided a relative assessment of expression of
antigenic epitopes by the rVV-expressed proteins. In addition,
that A.92RW020 Env was able to bind sCD4 and upregulate
MAb 17b binding provided additional rationale for testing this
Env as an immunogen.
Immunogenicity of consensus and WT HIV-1 Envs
To determine the ability of gp120, gp140ΔCFI, and
gp140ΔCF envelope constructs to induce antibodies that
neutralize HIV-1 primary isolates, we immunized guinea pigs
with 100 μg of glycoprotein in RIBI adjuvant. Sera collected after
4 or 5 immunizations were tested for neutralizing activity using a
panel of pseudoviruses containing the full-length (gp160) Env
proteins of subtype A, B, and C primary isolates. Sera of guinea
pigs immunized with B.6101 gp120 induced neutralizing
activities against three (B.BaL, B.SS1196, and B.SF162) of ten
subtype B viruses and did not significantly neutralize any subtype
C and A viruses. As previously reported (Liao et al., 2004),
immune sera of animals immunized with B.BaL gp120 inducedogens
B.JRFL
gp140ΔCF
A.92RW020
gp140ΔCFI
C.97ZA012
gp140ΔFI
B.BaL
gp120
B.6101
gp120
+* +* +* +* +*
++ + ND ++ −
++ + + ++ ++
− + − − −
++ + − ++ ++
− − − + −
+ + − ++ −
++ ++ − ++ ++
− − + +++ +
++ − − − −
+ − − − −
+* +* − +* +*
essed by injecting Env proteins at 150 μg/ml over A32, CD4, or irrelevant mAb
after subtraction of non-specific binding to the control surface.
ratios of each MAb to Env proteins captured on either immobilized T8 or A32
n RU. Binding ratios were scored as follows: + = or >0.05; ++ = >0.5; ++ = >1.0;
Table 2
Neutralization titers of guinea pigs immunized with HIV-1 subtype B monomeric gp120 immunogens
HIV-1 isolate B.6101 gp120 B.Bal gp120
Guinea pig number Guinea pig number
858 859 860 861 889 890 891 902
B.BX08a 21 20 <20 24 368 540 637 <20
B.QH0692.42 <20 <20 <20 <20 27 38 55 45
B.QH0515.1 <20 <20 <20 <20 <20 36 <20 40
B.BaL.26 107 166 201 540 112 1844 1475 507
B.SS1196.1 141 165 210 577 105 2395 2475 1475
B.SF162.LS 265 180 227 1298 530 130 1397 424
B.JRFL-MCb <20 <20 <20 <20 <20 23 43 <20
B.BG1168.1 <20 <20 <20 <20 <20 <20 <20 <20
B.3988.25 <20 <20 <20 <20 <20 <20 <20 <20
B.6101.10 <20 <20 <20 <20 <20 <20 <20 <20
*50% Neutralization titers of serum after 4th or 5th immunizations as determined in the pseudotyped HIV-1 neutralization assays as described in Materials and
methods. Neutralization was considered positive (number in bold) if the titer of post-immune serum minus the titer of pre-immune bleed serum was >30. Guinea pigs
anti-sera were tested as negative against 11 subtype C-pseudotyped viruses including TV-1.21, DU123.6, DU172.17, 02ZM233.PB6, 92BR025.9, 02ZM197.PB7,
96ZM651.2, DU151.2, 97ZA012.29, DU422.01, and DU156.12, and 2 subtype A-pseudotyped viruses, 92RWO20.2 and 92UG037.02. ND = not done.
a Assayed in Luc M7 cells using virus stock grown in PBMC.
b A full-length molecular clone and the assay stock of virus were produced by transfection in 293T cells.
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B.SS1196, B.SF162, and the autologous BaL) out of ten subtype
B viruses tested but failed to induce antibodies that neutralized
subtype C and subtype A viruses (Table 2).
We next compared the ability of the consensus and WT
gp140 Envs to induce neutralizing antibodies against a panel of
Tier 1 and Tier 2 HIV-1 Env-containing pseudovirions (Mascola
et al., 2005) (Table 3). Of the WT proteins, we found that B.Table 3
Neutralization titers of guinea pigs immunized with HIV-1 subtype A, B, C, and gr
HIV-1 Isolate 92RW020 gp140ΔCFI
(subtype A)
JRFL gp140ΔCF
(subtype B)
Guinea pig number Guinea pig number
854 855 856 857 791 793 796
B.BX08b <20 <20 <20 <20 23 22 <20
B.QH0692.42 34 <20 <20 36 108 <20 <20
B.SS1196.1 115 83 100 150 2203 2095 506
B.SF162.LS 1546 412 1301 984 1489 1888 92
B.JRFL-MCc <20 <20 <20 <20 <20 <20 <20
C.TV-1.21 540 443 449 711 <20 <20 <20
C.DU123.6 41 <20 48 37 <20 <20 <20
C.DU172.17 <20 <20 <20 <20 <20 <20 <20
C.02ZM233M.PB6 <20 <20 <20 <20 <20 <20 <20
C.92BR025.9 403 168 258 311 <20 <20 <20
C.02ZM197M.PB7 <20 <20 <20 27 23 22 <20
A.92RW020.2 150 71 100 106 <20 <20 <20
A.92UG037.01 <20 <20 <20 <20 <20 <20 <20
CON-S 44 <20 27 112 22 26 <20
CON6 27 <20 22 45 <20 <20 <20
a 50% neutralization titers of serum after 4th or 5th immunizations as determined
methods. Neutralization was considered positive (number in bold) if the titer of post-im
sera were assayed against additional subtype B pseudotyped viruses, BG1168.1, 3
96ZM651.2, DU151.2, DU422.01, and DU156.12, and were negative. In addition, an
855, 856, and 857, were assayed against additional 7 subtype A pseudotyped viruse
ND = not done.
b Assayed in Luc M7 cells using virus stock grown in PBMC.
c A full-length molecular clone, and the assay stock of virus were produced by traJRFL and C.97ZA012 Envs induced the least cross-reactive
neutralizing antibodies, with neutralization of only B.SF162,
and minimal neutralization of C.TV-1 and C.92BR025.9
subtype C pseudovirions as well as group M consensus CON-
S and CON6 Env-pseudotyped viruses. The subtype A Env
protein induced a broader neutralizing antibody response, with
neutralizing activity detectable against two subtype B (B.
SS1196, B.SF162), two subtype C (C.TV-1 and C.92BR025.9),oup M consensus (CON-S) Env immunogensa
97ZA012 gp140ΔCFI
(subtype C)
CON-S gp140ΔCFI
Guinea pig number Guinea pig number
797 862 863 864 865 776 777 778 780
<20 <20 <20 <20 <20 1196 412 4856 1817
<20 <20 <20 <20 <20 109 <20 <20 <20
489 23 27 <20 <20 796 296 1339 423
290 128 421 88 106 31,224 8186 41,667 13,369
<20 <20 <20 <20 <20 <20 <20 <20 <20
<20 93 148 <20 <20 1339 770 2442 724
<20 <20 115 <20 <20 176 329 387 378
<20 <20 <20 <20 <20 <20 235 <20 213
<20 <20 <20 <20 <20 84 61 86 43
<20 55 50 <20 39 1819 1408 3207 1336
<20 21 22 <20 <20 <20 33 30 <20
<20 <20 <20 <20 <20 116 204 95 177
<20 <20 <20 <20 <20 <20 <20 <20 <20
ND 58 72 183 24 819 1091 25 <20
ND 53 30 <20 <20 30 <20 <20 28
in the pseudotyped HIV-1 neutralization assays as described in Materials and
mune serumminus the titer of pre-immune bleed serum was >30. All guinea pig
988.25, and 6101.10, and subtype C pseudotyped viruses, 02ZM197M.PB7,
ti-CON-S sera, Nos. 776, 777, 778, and 780, and anti-92RW020 gp140 sera, 854,
s (93TH976.01, Q23, Q168, Q259, Q461, Q769, and Q842) and were negative.
nsfection in 293T cells.
Table 4
Geometric means of neutralization titers of guinea pigs immunized with CON-S Env gp140ΔCFI combined with other Envsa
HIV-1 isolate CON-S gp140ΔCFI CON-S gp140ΔCFI+C.97ZA012
gp140ΔCFI
CON-S gp140ΔCFI+B.Bal gp120
Geometric mean Geometric mean P valueb Geometric mean P valueb
B.SF162.LS 17,697 5451 0.004 16,846 NS
B.BX08c 75 154 NS 152 NS
B.QH0692.42 48 27 0.03 29 NS
B.BaL.26 1159 85 0.001 1028 NS
B.SS1196.1 627 89 0.02 880 NS
C.TV-1.21 1165 275 0.01 530 NS
C.DU123.6 59 21 NS 36 NS
C.92BR025.9 1314 360 0.003 708 NS
a Neutralization geometric means (GMT) of guinea pig sera after the 4th or 5th immunizations as determined in the pseudotyped HIV-1 neutralization assays as
described in Materials and methods.
b Data for CON-S gp140ΔCFI were from animals additional to those in Table 3. P values were obtained when comparison was made with GMT of guinea pigs
immunized with CON-S gpΔ140CFI Env alone. For CON-S gp140ΔCFI as well as CON-S gp140ΔCFI+97ZA012 gp140ΔCFI, n = 4; for CON-S gp140ΔCFI+BaL
gp120, n = 3. NS = not statistically significant.
c Assayed in Luc M7 cells using virus stock grown in PBMC.
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viruses (Table 3). There was minimal neutralization activity
against CON6 Env-pseudotyped virus and no reactivity against
seven additional subtype A primary viruses (Table 3, legend). In
contrast, the broadest neutralization response was observed with
the CON-S Env immunogen. Specifically, we found that CON-
S gp140ΔCFI envelope induced neutralizing antibodies that
neutralized four subtype B (B.BX08, B.QH0692, B.SS196, and
B.SF162), four subtype C (C.TV-1, C.DU123, C.DU172, and
C.92BR025.9), and one subtype A (A.92RW020) isolate
(Table 3). Moreover, the titers of neutralizing antibodies
induced by CON-S gp140ΔCFI against most pseudoviruses
were higher than those induced by WT Envs. In additional
repeat experiments summarized in Table 4, four of four CON-
S Env-immunized animals also had neutralizing activity to B.
QH0692 and B.BaL pseudoviruses.
Next, we tested anti-CON-S and anti-C.97ZA012 guinea
pig sera against B.SF162 and C.TV-1 in PBMC-based HIV-1
neutralization assays to verify the results obtained in theTable 5
Neutralization titers of guinea pigs immunized with CON6 gp140ΔCF and gp140Δ
HIV-1 Isolate CON6 gp140▵CF
Guinea pig number
770 771 772
B.BX08a 520 257 428
B.QH0692.42 46 55 58
B.SS1196.1 398 306 284
B.SF162.LS 791 151 34
B.JRFL-MCb <20 <20 <20
B.BG1168.1 <20 <20 <20
B.3988.25 <20 <20 <20
B.6101.10 <20 <20 <20
CON6 65 151 48
* 50% neutralization titers of serum after 4th or 5th immunizations as determined
methods. Neutralization was considered positive (number in bold) if the titer of post-
sera were also tested as negative against 11 subtype C-pseudotyped viruses includin
96ZM651.2, DU151.2, 97ZA012.29, DU422.01, DU156.12, and 2 subtype A-pseud
a Assayed in Luc M7 cells using virus stock grown in PBMC.
b A full-length molecular clone and the assay stock of virus were produced by trapseudotyped HIV-1 neutralization assays. We found that
CON-S guinea pig sera neutralized both B.SF162 (geometric
mean titer of 276, n = 8) and C.TV-1 (geometric mean titer of
100, n = 8), whereas anti-C.97ZA012 guinea pig did not
neutralize either B.SF162 or C.TV-1 (geometric mean titer
<20, n = 4). We had previously observed that CON6
gp140ΔCF induced antibodies that neutralized selected
subtype B but not non-B viruses (Gao et al., 2005). To
examine whether enhanced induction of neutralizing anti-
bodies by CON-S was due to the absence of the immunodo-
minant gp41 region in the ΔCFI constructs, we generated the
corresponding CON6 gp140ΔCFI construct (Chakrabarti et al.,
2002; Gao et al., 2005). Immunization studies in guinea pigs
showed that the additional deletion of 28 amino acids of the
gp41 ectodomain had no effect on the immunogenicity of
CON6 Env (Table 5). Both CON6 gp140ΔCF and CON6
gp140CΔFI oligomers induced antibodies that neutralized B.
BX08, B.QH0692 and B.SS1196 amonga totalofsevensubtype
B Env-containing pseudovirions.CFI immunogens
CON6 gp140ΔCFI
Guinea pig number
775 781 783 784 786
189 1930 390 2979 645
77 <20 91 100 76
222 482 323 1151 446
200 578 2022 249 351
<20 <20 169 <20 <20
<20 <20 <20 <20 <20
<20 <20 <20 <20 <20
<20 <20 <20 <20 <20
<20 <20 1308 41 260
in the pseudotyped HIV-1 neutralization assays as described in Materials and
immune serum minus the titer of pre-immune bleed serum was >30. Guinea pigs
g TV-1.21, DU123.6, DU172.17, 02ZM233.PB6, 92BR025.9, 02ZM197.PB7,
otyped viruses, 92RWO20.2 and 92UG037.02.
nsfection in 293T cells.
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neutralize the CON-S or CON6 pseudoviruses. We found that
two of four anti-CON-S antisera neutralized CON-S pseudovirus
but did not significantly neutralize CON6 (Table 3), whereas six
of eight animals immunized with CON6 Envs-developed
antibodies that neutralized CON6 pseudovirus (Table 5).
Ability of CON-S variable loop peptides to absorb the
neutralizing activity of CON-S Env-induced antibodies
Most of the amino acid sequence differences between CON6
and CON-S Envs are localized in the variable loops (Fig. 4). To
determine if any particular variable loop contributed to the ability
of CON-S to induce antibodies that neutralized non-subtype B
isolates, we synthesized, purified, and tested peptides derived
from the V1, V2, V3, V4, and V5 loop regions of both CON-S
and CON6 Envs for their ability to absorb the neutralizing
activity against B.SS1196, C.TV-1, C.DU123, C.DU172, and
C.02ZM233M and A.92RW020 Env-pseudotyped viruses.
Whereas CON-S V1, V2, V4, or V5 peptides did not absorb
the neutralizing activity of anti-CON-S sera to any of 6 Env-
containing pseudoviruses tested (Fig. 5), 86% of the neutra-
lizing activity of anti-CON-S sera for B.SS1196 and 92% of the
neutralizing activity for C.TV-1 were absorbed by CON-S V3
peptide. In addition, an average of 48% of the neutralizing
activity of anti-CON-S sera for non-subtype B Env-pseudo-
typed viruses including C.DU123 (67%), C.DU172 (33%),
C.02ZM233M (43%), and A.92RW020 (48%) was absorbed by
the CON-S V3 peptide (Fig. 5A). In comparison, the CON6 V3
peptide had weaker but significant ability to absorb neutraliza-
tion activity of anti-CON-S sera for subtype B pseudoviruses
(upper left panel in Fig. 5A). Whereas CON6 V3 peptide
absorbed 50% of the neutralizing activity of anti-CON-S sera
for B.SS1196 pseudovirus, the CON6 V3 peptide could not
absorb any CON-S-induced anti-subtype C neutralizing anti-
bodies (Fig. 5A). Thus, the CON6 V3 peptide could assume a
conformer structure to partially absorb the CON-S-induced
subtype B neutralizing antibodies but could not assume a
conformer sufficiently similar to CON-S V3 peptide to absorb
the CON-S-induced subtype C neutralizing antibodies.
CON6 V1, V2, V4, and V5 peptides did not absorb
neutralizing activity induced by either CON6 (Fig. 5B) orFig. 4. Amino acid differences in CON6 gp140ΔCFI and CON-S gp140ΔCFI. Diffe
numbers beneath the amino acids. The dashed line(s) indicate the deletion of a.a. at thCON-S gp140ΔCFI proteins (data not shown), although CON6
V3 peptides did absorb CON6 Env-induced neutralizing activity
against B.SS1196. Further, none of CON-S V1, V2, V3, V4, and
V5 peptides absorbed the anti-B.SS1196 neutralizing antibodies
induced by CON6 gp140ΔCFI (Fig. 5C).
Because high titers of ELISAbinding antibodywere detected in
anti-CON-S sera that reacted with the CON-SV2 and V3 peptides
(data not shown), we tested if a combination of CON-SV2 and V3
peptides could absorb more neutralization activity of anti-CON-S
sera than CON-S V3 peptide alone. We found no additive or
synergistic effect of CON-S V2 peptide mixed with CON-S V3
peptide on the absorption of neutralizing activity (data not shown).
Certain HIV-1 V3 peptides have been shown to be potent
inducers for the induction of antibodies that neutralize T cell
line adapted isolates and selected HIV-1 primary isolates
(Palker et al., 1988, 1989; Rusche et al., 1988; LaRosa et al.,
1990; Liao et al., 2000; Haynes et al., 2006). Because the CON-
S V3 peptide absorbed a major proportion of the neutralizing
activity of anti-CON-S gp140ΔCFI sera, we next tested if the
same V3 peptide used in the absorption studies or an optimally
immunogenic CON-S V3 peptide (GTH1-V3) that contains the
CON-S V3 loop sequence with an N-terminal T helper gag p24
epitope (GTH1) could induce a similar spectrum of neutralizing
antibodies as the CON-S gp140ΔCFI Env. We found in 4
guinea pigs for each peptide that neither CON-S V3 peptide nor
CON-S GTH1-V3 peptide induced antibodies that neutralized
subtype B or C HIV-1 Env containing pseudoviruses (data not
shown). Thus, CON-S V3 peptides could absorb much of the
anti-CON-S neutralizing activity, but when used as immuno-
gens themselves, they could not induce the neutralizing activity,
indicating a requirement of the CON-S V3 conformation in the
context of the gp140 Env for immunogenicity.
Induction of neutralizing antibodies with CON-S gp140ΔCFI
combined with other Envs
We have previously reported that B.BaL gp120 induced
antibodies that neutralized approximately 40% of subtype B
isolates tested (Liao et al., 2004). To determine if the ability of
CON-S gp140ΔCFI to induce HIV-1 neutralizing antibodies
could be enhanced by immunization with a combination of
CON-S and other HIV-1 envelope immunogens, we immunizedrences were indicated using single letter code. Positions of a.a. are indicated by
e position. Amino acid differences in the Env variable loops are shown in boxes.
Fig. 5. Specificity of neutralization activity of anti-CON-S and anti-CON6 guinea pig sera. Absorption assays were performed as described in the Materials and
methods. Results were plotted on y axis as mean % of neutralization activity remaining after absorption of 4 serum samples with the indicated CON-S or CON6 V1,
V2, V3, V4, and V5 peptides (V1–V5 CON-S or CON6). The error bars indicated the standard error deviations. Panel A shows the neutralization activity against six
HIV-1 primary isolates by anti-CON-S sera after absorption with CON-S variable loop peptides or CON6 V3 peptide as indicated in the bottom of the column plots.
Panel B shows the neutralization activity against B.SS1196 by anti-CON6 sera after absorption with CON6 variable loop peptides. Panel C shows the neutralization
activity against B.SS1196 by anti-CON6 sera after absorption with CON-S V3 variable loop peptides.
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C.97ZA012 gp140ΔCFI or B.BaL gp120 (100 μg of each Env/
injection).We found that immune sera of guinea pigs immunized
with the combination immunogens neutralized the same number
of HIV-1 isolates with essentially the same antibody titers
compared to immune sera of guinea pigs immunized with CON-
S gp140ΔCFI alone (Table 4). Interestingly, not only did the
combination of CON-S with subtype C gp140ΔCFI protein not
enhance the ability to induce neutralizing antibodies, the
neutralizing antibody titers induced by the combination of WT
C+ CON-S gp140ΔCFI were significantly reduced (Table 4).
For example, the addition of C.97ZA012 gp140ΔCFI to CON-S
gp140ΔCFI reduced the geometric mean titer (GMT) of anti-B.
SF162 neutralizing antibodies from 17.697 to 5.451 (P = 0.004,
n = 4) and of anti-C.TV-1 neutralizing antibodies from 1.165 to
275 (P = 0.01, n = 4). Thus, not only was the subtype C Env not
additive in inducing neutralizing antibodies, the WT subtype C
Env was in some way suppressing the neutralizing antibody
responses induced by CON-S gp140ΔCFI.
Discussion
In this study, we have compared the ability of a group M
consensus Env immunogen (CON-S gp140ΔCFI) to induce
neutralizing antibodies to that of five WT Env constructs
representing subtypes A, B, and C. Among the wild-type Env
immunogens, the subtype A Envs induced antibodies in guinea
pigs that neutralized a subset of subtype B and C Envs.
However, the group M consensus Env, CON-S, elicited cross-
subtype neutralizing antibodies with similar or greater breadth
and titer than WT Envs.
Seaman et al. (2005) have studied the immunogenicity of
WTA (A.92RW020), WT B (B.HXB2 with BaLV3 loop), and
WT C Envs (C.97ZA012) and showed that when formulated as
a DNA prime, recombinant adenovirus (rAd) boost, the WT A
was superior to WT B and C Env genes for the induction of
neutralizing antibodies. They also showed that the WT C Env
gene induced minimal neutralizing antibodies to primary
isolates (Seaman et al., 2005). Our studies using the same
subtype A and C recombinant protein gp140ΔCFI immunogens
confirm these studies and further show that the WT C
immunogen was suppressive of subtype B and C neutralizing
responses induced by CON-S. These studies may in part
provide an explanation for the limited magnitude and breadth of
neutralization responses that have been induced by subtype C
immunogens. In this regard, Seaman et al. studied combinations
of C.97ZA012 Env genes with WT subtype B and A Env genes
and did not see suppression of antibody responses in Env gene
combinations that included WT C. It is possible that this was
due to the use of DNA prime, rAd boost, or due to specific
interactions of subtype C and CON-S Env in the induction of
neutralizing antibodies. Nonetheless, additional subtype C Envs
should be studied to determine if the subtype C Env in some
generic manner inhibits the induction of anti-HIV-1 neutralizing
antibodies.
Our year 2001 group M consensus CON-S Env now
represents the third centralized Env that has been studied forimmunogenicity (Gao et al., 2005; Doria-Rose et al., 2005).
Here and in our previous study of CON6 Env, we show that this
immunogen induces neutralizing antibodies only against a
subset of subtype B viruses. Similarly, Doria-Rose et al. reported
only weak neutralizing responses exclusively against subtype B
viruses and no neutralization of the non-subtype B strains
(subtype C isolate S080 and clade E isolate CM244) using an
ancestral subtype B Env gene in a DNA prime and recombinant
protein boost immunization regimen (Doria-Rose et al., 2005).
One difference of possible significance between the ancestral B
antigen and the M group consensus sequences described here is
that the B ancestor sequence had very long hypervariable loops
with more glycosylation sites than natural strains.
A critical issue in HIV-1 vaccine development is to
determine the criteria for choosing any one particular Env or
combination of Envs for inclusion into candidate immunogens
(Hurwitz et al., 2005; Rollman et al., 2004; Srivastava et al.,
2004; VanCott et al., 1997, 1999; Barnett et al., 2001; Fouts et
al., 2002; Hewer and Meyer, 2002; Dong et al., 2003; Seaman et
al., 2005; Mascola et al., 2005; Poon et al., 2005; Lian et al.,
2005; Pal et al., 2005). Our data indicate that consensus env
genes such as CON-S can be designed that express the same
antigenic epitopes as WT Envs but have improved immunoge-
nicity. Our observations demonstrate that iterative improvement
of Env immunogenicity, whether using centralized and/or
structure based designs, is achievable. The variable loops of
CON-S were purposefully shortened to mimic the shorter
variable loops observed for env genes of acute subtype A and C
infections. Several reports indicate that exposure of certain
neutralizing epitopes participating in the envelope CD4 and co-
receptor binding can be increased by mutations and deletions of
the variable domains of HIV-1 envelope glycoprotein (Kang et
al., 2005; Gzyl et al., 2004; Kim et al., 2003; Barnett et al.,
2001; Wyatt et al., 1993). Yang et al. (2004) have demonstrated
induction of improved levels of neutralizing antibodies with
Envs with shortened V3 loops. Conserved neutralization
epitopes of receptor binding sites are located in the recessed
core of HIV-1 envelope, partially masked by variable loops and
glycosylations. Thus, to elicit antibodies that can broadly
neutralize genetically diverse HIV-1 isolates, it may be
important to design vaccines in which the conserved neutral-
izing epitopes are exposed. However, it remains to be
determined that if the enhanced ability of CON-S Env for
induction of broadly reactive neutralizing antibody was
contributed by the shortened variable loops in CON-S Env. In
this regard, we have recently determined if anti-CON-S sera
have antibodies capable of blocking the binding of MAbs 2F5
and 2G12 as well as sCD4 to CON-S gp140 oligomers.
Whereas anti-CON-S sera did not block the binding of MAbs
2F5 and 2G12 to CON-S Env, anti-CON-S sera (n = 4) did
block >75% binding of sCD4 to CON-S Env at 1:100 dilution
(data not shown). Thus, anti-CD4 binding site antibodies may
contribute to the neutralization of non-subtype B isolates by
anti-CON-S sera.
Given the limited heterogeneity of most transmitted HIV-1
quasi-species (Chohan et al., 2005; Derdeyn et al., 2004), it is
reasonable to expect continued improvement in centralized
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multiple HIV-1 subtypes becomes available. Such a database is
currently under development (Korber et al., unpublished
observations). Furthermore, experiments are underway to test
the next generation M group consensus Envs based on the
2003 HIV-1 Sequence Database, to include only the minimal
conserved elements in the hypervariable loops. It is also
interesting to note that whereas V3 peptides absorbed > 85%
anti-CON-S neutralizing activity for the Tier 1 B.SS1196 and
C.TV-1 viruses, V3 peptides were only able to reduce 48% of
the neutralizing activity for the Tier 2 C.DU123, C.DU172,
C.92M233M, and A.92RW020 strains. It will be important to
construct a V3-deleted CON-S to determine if, in the absence
of V3, CON-S can induce enhanced levels of non-V3
neutralizing antibody.
That much of the neutralizing activity induced by CON-S
Env was absorbed by the CON-S V3 peptide was of interest and
suggested that the V3 loop of CON-S gp140ÄCFI was in a
conformation required for induction of neutralizing antibodies to
subtype C primary viruses. The V3 of subtype C is not
particularly variable (Ping et al., 1999; Williamson et al., 2003;
Gaschen et al., 2002). As such, the inability of CON-S to induce
neutralizing antibodies to six of eleven subtype C strains
suggests that like subtype B (Sullivan et al., 1998), theWTCV3
loop may not be accessible on the surface of the virion in a
substantial number of WTsubtype C Envs. Alternatively, the V3
loop may be accessible, but anti-V3 antibodies may bind with
insufficient strength to neutralize HIV-1 (Gorny et al., 2004).
In this regard, it is important to note that the CON6, WT
subtype C, and CON-S Envs all have GPGQ at the tips of the
V3 loops, yet only CON-S induced any antibodies against
subtype C viruses (Table 5). Gorny et al. (2005) have recently
demonstrated that human anti-V3 MAbs derived from patients
with non-B HIV-1 with GPGQ V3s have greater breadth
against HIV-1 primary isolates than human MAbs derived
from patients with subtype B HIV-1 with GPGR V3s (Zolla-
Pazner et al., 2004). This suggests that in patients with chronic
HIV-1 infection, the GPGQ V3 in select patients is able to
induce broadly neutralizing antibodies against a functional
conformation of V3. However, the opposite result is observed
in the setting of animals immunized with either V3
immunogens or V3 containing WT Envs, in that subtype B
V3s and oligomeric Envs induce neutralizing antibodies with
more breadth than do subtype C V3 peptides and subtype C
Envs (Haynes et al., 2006; Liao et al., 2004; Haynes, B.F.,
Korber, B.T., unpublished). Whether this difference is due to the
duration of immunizations, adjuvant formulations, or conforma-
tions of the Env and/or V3 Env subunits remain to be
determined. Whatever the explanation, the gp140 CON-S Env
differs from WT subtype C Env in its ability to induce
neutralizing antibodies. Study of the structural differences
between CON6, CON-S, and WT Envs should provide
important information regarding the design of immunogens for
induction of neutralizing antibodies with more breadth than is
currently attainable.
In summary, the results reported here suggest that with
continued iterative improvements in design, centralized Envimmunogens may be of value for the induction of cross-reactive
neutralizing antibody responses.
Materials and methods
Design of the CON-S consensus Env gene
CON-S was derived by aligning the consensus env sequences
of group M subtypes A (including A, A1, and A2), B, C, D, F
(including F1 and F2), and G from the 2001 HIV sequence
database as described (http://hiv-web.lanl.gov/content/hiv-db/
CONSENSUS/M_GROUP/Consensus.html) (Table 6). Only
full-length proteins and one sequence per individual were
included in the alignment. In regions outside of the variable
loops, this consensus is virtually identical to a model of the
ancestral sequence of the M group based on maximum
likelihood phylogenies (Gaschen et al., 2002; Nickel et al.,
2003). V3 was readily aligned and was treated the same as the
more conserved Env regions. The highly variable loop regions
evolve by insertion and deletion and are particularly difficult to
align. To design the hypervariable loop regions for CON-S, we
made hand alignments that first brought potential N-linked
glycosylation sites and cysteines into alignment, and then
brought repeated sequence motifs within loops into alignment.
Amino acids present in the majority of positions were retained
for each subtype, and a consensus of consensuses was generated
(Table 6). This procedure, by design, generated hypervariable
loop sequences (V1, V2, V4, and V5) that tended to comprise a
shorter range of lengths found among natural strains. This result
was intended because shorter length V1, V2, V4, and V5 loops
might expose regions around the variable loops that might
conserve neutralizing determinants.
Expression of recombinant HIV-1 envelopes
The CON-S env gene was generated by converting amino
acid sequences of CON-S to nucleotide sequences employing
the codon usage of highly expressed human housekeeping genes
(Andre et al., 1998) and de novo synthesized (Table 6). HIV-1
gp140 Envs with the deletion of the cleavage (C) site, fusion (F),
and immunodominant (I) region in gp41 were named as
gp140ΔCFI, and HIV-1 gp140 Envs with the deletion of only
the cleavage (C) site and fusion (F) domain were named as
gp140ΔCF. CON-S gp140ΔCFI and CON6 gp140ΔCFI were
generated by PCR by introducing a stop codon before the
membrane-spanning domain (YIKIFIMIVGGLIGLRIVFAVL-
SIVN) (Table 6) (Chakrabarti et al., 2002; Gao et al., 2005).
CON6 gp140ΔCF and wild-type (WT) subtype B (B.) JRFL
gp140ΔCF env genes were constructed as described (Gao et al.,
2005). HIV-1WTsubtype A (A.) 92RW020) and subtype C (C.)
97ZA012 env gp140ΔCFI constructs have previously been
reported (Seaman et al., 2005). HIV-1 primary isolate B.6101
env gp120 was constructed by introducing a stop codon at
the cleavage site using the methods as described (Gao et al.,
2005). Recombinant HIV-1 B.BaL gp120 was obtained from the
AIDS Reagent repository (Liao et al., 2004). Recombinant
vaccinia viruses (rVVs) expressing CON6 gp140ΔCF, CON6
Table 6
Amino acid and nucleotide sequences of CON-S Env gp160 a
MRVRGIQRNCQHLWRWGTLILGMLMICSAAENLWVTVYYGVPVWKEANTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTNVNVTNTTNNTEEKGEIKNCSFNITTEIRDKKQKVYALFYRLDVVPIDDNNNNSSNYRLINCNTSAIT
QACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGTGPCKNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENITNNAKTIIVQLNESVEINCTRPNNNTRKSI
RIGPGQAFYATGDIIGDIRQAHCNISGTKWNKTLQQVAKKLREHFNNKTIIFKPSSGGDLEITTHSFNCRGEFFYCNTSGLFNSTWIGNGTKNNNNTNDTITL
PCRIKQIINMWQGVGQAMYAPPIEGKITCKSNITGLLLTRDGGNNNTNETEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVEREKRAVGIGA
VFLGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTTVPWNSSWSNK
SQDEIWDNMTWMEWEREINNYTDIIYSLIEESQNQQEKNEQELLALDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIVFAVLSIVNRVRQGYSPLSFQT
LIPNPRGPDRPEGIEEEGGEQDRDRSIRLVNGFLALAWDDLRSLCLFSYHRLRDFILIAARTVELLGRKGLRRGWEALKYLWNLLQYWGQELKNSAISL
LDTTAIAVAEGTDRVIEVVQRACRAILNIPRRIRQGLERALL
Nucleotide sequence
ATGCGCGTGCGCGGCATCCAGCGCAACTGCCAGCACCTGTGGCGCTGGGGCACCCTGATCCTGGGCATGCTGATGATCTGCTCCGCCGCCGAGAACC
TGTGGGTGACCGTGTACTACGGCGTGCCCGTGTGGAAGGAGGCCAACACCACCCTGTTCTGCGCCTCCGACGCCAAGGCCTACGACACCGAGGTGC
ACAACGTGTGGGCCACCCACGCCTGCGTGCCCACCGACCCCAACCCCCAGGAGATCGTGCTGGAGAACGTGACCGAGAACTTCAACATGTGGAAG
AACAACATGGTGGAGCAGATGCACGAGGACATCATCTCCCTGTGGGACCAGTCCCTGAAGCCCTGCGTGAAGCTGACCCCCCTGTGCGTGACCCTG
AACTGCACCAACGTGAACGTGACCAACACCACCAACAACACCGAGGAGAAGGGCGAGATCAAGAACTGCTCCTTCAACATCACCACCGAGATCCG
CGACAAGAAGCAGAAGGTGTACGCCCTGTTCTACCGCCTGGACGTGGTGCCCATCGACGACAACAACAACAACTCCTCCAACTACCGCCTGATCAA
CTGCAACACCTCCGCCATCACCCAGGCCTGCCCCAAGGTGTCCTTCGAGCCCATCCCCATCCACTACTGCGCCCCCGCCGGCTTCGCCATCCTGAAG
TGCAACGACAAGAAGTTCAACGGCACCGGCCCCTGCAAGAACGTGTCCACCGTGCAGTGCACCCACGGCATCAAGCCCGTGGTGTCCACCCAGCT
GCTGCTGAACGGCTCCCTGGCCGAGGAGGAGATCATCATCCGCTCCGAGAACATCACCAACAACGCCAAGACCATCATCGTGCAGCTGAACGAGTC
CGTGGAGATCAACTGCACCCGCCCCAACAACAACACCCGCAAGTCCATCCGCATCGGCCCCGGCCAGGCCTTCTACGCCACCGGCGACATCATCGG
CGACATCCGCCAGGCCCACTGCAACATCTCCGGCACCAAGTGGAACAAGACCCTGCAGCAGGTGGCCAAGAAGCTGCGCGAGCACTTCAACAACA
AGACCATCATCTTCAAGCCCTCCTCCGGCGGCGACCTGGAGATCACCACCCACTCCTTCAACTGCCGCGGCGAGTTCTTCTACTGCAACACCTCCGG
CCTGTTCAACTCCACCTGGATCGGCAACGGCACCAAGAACAACAACAACACCAACGACACCATCACCCTGCCCTGCCGCATCAAGCAGATCATCAA
CATGTGGCAGGGCGTGGGCCAGGCCATGTACGCCCCCCCCATCGAGGGCAAGATCACCTGCAAGTCCAACATCACCGGCCTGCTGCTGACCCGCGA
CGGCGGCAACAACAACACCAACGAGACCGAGATCTTCCGCCCCGGCGGCGGCGACATGCGCGACAACTGGCGCTCCGAGCTGTACAAGTACAAGG
TGGTGAAGATCGAGCCCCTGGGCGTGGCCCCCACCAAGGCCAAGCGCCGCGTGGTGGAGCGCGAGAAGCGCGCCGTGGGCATCGGCGCCGTGTTC
CTGGGCTTCCTGGGCGCCGCCGGCTCCACCATGGGCGCCGCCTCCATCACCCTGACCGTGCAGGCCCGCCAGCTGCTGTCCGGCATCGTGCAGCAG
CAGTCCAACCTGCTGCGCGCCATCGAGGCCCAGCAGCACCTGCTGCAGCTGACCGTGTGGGGCATCAAGCAGCTGCAGGCCCGCGTGCTGGCCGTG
GAGCGCTACCTGAAGGACCAGCAGCTGCTGGGCATCTGGGGCTGCTCCGGCAAGCTGATCTGCACCACCACCGTGCCCTGGAACTCCTCCTGGTCC
AACAAGTCCCAGGACGAGATCTGGGACAACATGACCTGGATGGAGTGGGAGCGCGAGATCAACAACTACACCGACATCATCTACTCCCTGATCGAG
GAGTCCCAGAACCAGCAGGAGAAGAACGAGCAGGAGCTGCTGGCCCTGGACAAGTGGGCCTCCCTGTGGAACTGGTTCGACATCACCAACTGGCT
GTGGTACATCAAGATCTTCATCATGATCGTGGGCGGCCTGATCGGCCTGCGCATCGTGTTCGCCGTGCTGTCCATCGTGAACCGCGTGCGCCAGGGCT
ACTCCCCCCTGTCCTTCCAGACCCTGATCCCCAACCCCCGCGGCCCCGACCGCCCCGAGGGCATCGAGGAGGAGGGCGGCGAGCAGGACCGCGAC
CGCTCCATCCGCCTGGTGAACGGCTTCCTGGCCCTGGCCTGGGACGACCTGCGCTCCCTGTGCCTGTTCTCCTACCACCGCCTGCGCGACTTCATCCT
GATCGCCGCCCGCACCGTGGAGCTGCTGGGCCGCAAGGGCCTGCGCCGCGGCTGGGAGGCCCTGAAGTACCTGTGGAACCTGCTGCAGTACTGGG
GCCAGGAGCTGAAGAACTCCGCCATCTCCCTGCTGGACACCACCGCCATCGCCGTGGCCGAGGGCACCGACCGCGTGATCGAGGTGGTGCAGCGC
GCCTGCCGCGCCATCCTGAACATCCCCCGCCGCATCCGCCAGGGCCTGGAGCGCGCCCTGCTGTAA
a Cleavage site and fusion domain are in italic font and underlined; the immunodominant region is highlighted in bold. The transmembrane and cytoplasmic domains
are underlined.
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A.92RW020 gp140ΔCFI, C.97ZA012 gp140ΔCFI, and
B.6101 gp120 genes were generated as previously described
(Earl, 1997; Moss and Earl, 1998). Identities of the individual
rVVs were confirmed by PCR and nucleotide sequence analysis.
Recombinant Env glycoproteins were purified from super-
natants of 293Tcell cultures infected with rVVs usingGalanthus
nivalis lectin-agarose (Vector Labs, Burlingame, CA) column
chromatography and stored at −70 °C until use.
MAbs
Human monoclonal antibodies (MAbs) known to bind
epitopes on gp120 (A32), the gp120 V3 loop (19b, F2A3,
39F), and the CCR5 binding site (17b) were kindly provided by
James Robinson (Tulane Medical School, New Orleans, LA)
(Rizzuto and Sodroski, 2000; Wyatt et al., 1998; Wyatt et al.,
1995; Xiang et al., 2002). MAbs 2F5, 4E10, and 2G12 were
gifts from Hermann Katinger at the University of Natural
Resources and Applied Life Sciences, Vienna, Austria. MAbIgG1b12 was the gift of Dennis Burton, Scripps Research
Institute, La Jolla, CA. MAb 447-52D and soluble CD4 (sCD4)
were obtained from the National Institutes of Health (NIH)
AIDS Research and Reference Reagent Program (Bethesda,
MD). T8 is a murine MAb that binds to the gp120 C1 region (a
gift from P. Earl, NIH).
SDS–PAGE and BN–PAGE
WT B.6101 and B.BaL gp120 proteins were analyzed by
SDS–PAGE. Blue native polyacrylamide gel electrophoresis
(BN–PAGE) analysis of CON-S, CON6, and WT HIV-1
envelope gp140ÄCFI or ÄCF proteins was carried out
according to the methods as described (Gao et al., 2005;
Schagger et al., 1994; Schulke et al., 2002) with modifications
due to the highly basic pIs of HIV-1 Env proteins. Briefly,
purified HIV-1 Env glycoproteins were diluted in a buffer
containing 50 mM MOPS (morpholinepropanesulfonic acid),
50 mM Tris–HCl (pH 7.7), 20% glycerol, and 0.05%
Coomassie blue. Protein samples were loaded onto a 3–8%
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electrophoresis was carried out for 1.5 h at 150 V with 50 mM
MOPS–50 mM Tris–HCl (pH 7.7)–0.03% Coomassie blue as
the cathode running buffer and 50 mM MOPS–50 mM Tris–
HCl (pH 7.7) as the anode buffer. Thyroglobulin, ferritin,
catalase, lactate dehydrogenase, and albumin (Amersham
Biosciences) with molecular weights of 669, 440, 232, 140,
and 66 kDa, respectively, were included in BN-PAGE as
molecular weight markers.
Surface plasmon resonance
Surface plasmon resonance assays were performed on a
BIAcore 3000 instrument and data analysis was performed with
BIAevaluation 3.0 software (BIAcore, Upsaala, Sweden). Anti-
gp120 MAbs (T8, A32, 17b, and 2G12) or sCD4 in 10 mMNa–
acetate buffer (pH 4.5) were directly immobilized to CM5 sensor
chips using a standard amine coupling protocol for protein
immobilization. Purified HIV-1 Env glycoproteins were flowed
over CM5 sensor chips at concentrations of 100 and 300 μg/ml,
respectively. Binding of HIV-1 envelope proteins was monitored
in real time at 25 °C with a continuous flow of phosphate-
buffered saline (150 mMNaCl, 0.005% surfactant P20 [pH 7.4])
at 10–30 μl/min (Alam et al., 2004; Gao et al., 2005).
Immunizations
Outbred guinea pigs were purchased from Jackson Laboratory
and housed in the Vivarium at Duke University Animal Research
Facility. Animals were studied under a protocol approved by the
AnimalUse andCareCommittee ofDukeUniversity. Guinea pigs
(4 animals per immunogen group) were immunized subcutane-
ously on day 0 and weeks 3, 6, 9, and 12 with 100 μg/injection of
recombinant HIV-1 Env gp140 or gp120 proteins formulated in
Ribi-CWS adjuvant (Corixa-Sigma, St. Louis, MO). When
combinations of two HIV-1 Env proteins as immunogens were
used, 100 μg of each Env protein for a total of 200 μg/injection
was administered. Serum samples were collected 10 days after
each immunization and stored at −30 °C until use.
Generation of pseudotyped viruses
CON-S and CON6 Env-pseudotyped viruses were generated
by co-transfection of CON-S gp160 or CON6 gp160 clones (in
pcDNA3.1) with pSG3ΔEnv (an env-minus backbone vector)
in 293T cells using the method as described (Derdeyn et al.,
2000; Wei et al., 2002, 2003). The same approach was used toTable 7
CON-S and CON6 Env variable loop peptides used in absorption assay
Variable region Amino acid sequence of CON-S
V1 TNVNVTNTTNNTEEKGEIKN
V2 TEIRDKKQKVYALFYRLDVVPIDDNNNNSSNYR
V3 TRPNNNTRKSIRIGPGQAFYATGDIIGDIRQAH
V4 NTSGLFNSTWIGNGTKNNNNTNDTITLP
V5 RDGGNNNTNETEIFRPGGGDgenerate stocks of pseudotyped HIV-1 viruses containing
subtypes A, B, and C Envs from primary HIV-1 isolates for
neutralization assays. Infectious titers of pseudotyped viruses
were determined in TZM-bl (JC53-BL) cells based on luciferase
(Luc) reporter gene expression using the method as described
(Montefiori, 2004). Briefly, TZM-bl cells in 96-well plates were
infected with 11 serial 5-fold dilutions of pseudotyped viruses in
quadruplicates for each dilution and incubated for 48 h.
Uninfected TZM-bl cells were used as negative controls. At
the end of incubation, Bright GloTM luciferase substract was
added. The relative luminescence units (RLU) of each well in
96-well microtiter tissue culture plates were measured by a
luminometer. Wells with RLU < 2.5 times over the negative
controls were considered as negative for the calculation of the
tissue culture infection doses (TCID50). TCID50 was calculated
using the Reed-Muench accumulative method as described
(Poli and Fauci, 2004).
Neutralization assays
Serum neutralizing antibody levels were measured against a
panel of pseudotyped HIV-1 viruses containing Envs from
subtype B (B.QH0692, B.SF162, B.SS1196, B.BaL, B.BG1168,
B.3988, and B.6101), subtype C (C.TV-1, C.DU123, C.DU172,
C.92ZM233M, C.92BR025, C.92ZM197M, C.96ZM651, C.
DU151, C.97ZA012, C.DU422, C.DU156, C.02ZM233M, and
C.02ZM197M), and subtype A (A.92RW010, A.92UG37,
A.93TH976.01, A.Q23, A.Q168, A.Q259, A.Q461, A.Q769,
and A.Q842). HIV-1 env genes were amplified from DNAs
derived from uncultured PBMC of HIV-1 patients or derived
from short-term PBMC cultures. Neutralization assays were
based on reductions in luciferase (Luc) reporter gene
expression after a single round of virus infection with
pseudotyped HIV-1 viruses in TZM-bl cells (Derdeyn et al.,
2000; Wei et al., 2002, 2003; Montefiori, 2004; Li et al.,
2005). Briefly, 200 TCID50 of virus were incubated with serial
3-fold dilutions of serum samples in triplicate in a total
volume of 150 μl for 1 h at 37 °C in 96-well flat-bottom
culture plates. Freshly trypsinized cells (10,000 cells in 100 μl
of growth medium containing 75 μg/ml DEAE dextran) were
added to each well. One set of control wells received cells plus
virus (virus control) and another set received cells only
(background control). After a 48-h incubation, 100 μl of cells
was transferred to a 96-well black solid plate (Costar) for
measurements of luminescence using Bright Glo substrate
solution as described by the supplier (Promega). Neutraliza-
tion titer was the dilution at which RLUs were reduced byAmino acid sequence of CON6
TNVRNVSSNGTETDNEEIKN
TELRDKKQKVYALFYRLDVVPIDDKNSSEISGKNSSEYYR
TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQAH
NTSGLFNSTWMFNGTYMFNGTKDNSETITLP
RDGGNNSNKNKTETFRPGGGD
280 H.-X. Liao et al. / Virology 353 (2006) 268–28250% compared to virus control wells after subtraction of
background RLUs. Neutralization was considered positive if
the titer of post-immune serum minus the titer of pre-immune
bleed titer was >30. For HIV-1 BX08 neutralization assays,
PBMC-derived replication competent virus was used in the
Luc M.7 assay as described (Montefiori, 2004; Gao et al.,
2005). For neutralization of JRFL, neutralization assays were
performed in the TZM-bl cells using JRFL virus that was
generated in 293T cells by transfection using an infectious
molecular clone as described (Derdeyn et al., 2000; Wei et al.,
2002, 2003). In CON6 and CON-S infectivity assays, TZM-bl
cells were pretreated with ADM3100 (CXCR4 inhibition),
TAK-799 (CCR5 inhibitors), or both before infection with Env
containing pseudovirions. Neutralization assays of HIV-1
primary isolates, SF162 and TV-1, were also performed in
PBMC-based neutralization assays by measuring reduction in
HIV-1 p24 antigen in PHA-activated PBMCs (Montefiori et
al., 1996; Bures et al., 2000).
Peptides
The CON-S and CON6 V1, V2, V3, V4, and V5 peptides
(Table 7) were synthesized by SynPep (Dublin, CA) using F-
MOC chemistry, purified by HPLC, and confirmed to be correct
by mass spectrometry.
For peptide absorption of neutralizing antibodies, serum
samples were diluted a minimum of 2-fold in PBS to
optimize peptide blocking and to yield approximate equal
concentrations of neutralizing antibodies in each sample
based on measured neutralizing antibody titers. Separate
portions of each diluted serum sample were incubated for
1 h with the V1, V2, V3, V4, or V5 loop peptides or
scrambled V3 control peptide (RGYFTRRNAPSNTARGR-
PILRRN), each at a final concentration of 50 μg/ml. As an
additional control, a portion of each diluted serum sample
was incubated with a volume of PBS equal to the volume of
peptide added to the other samples. Adsorbed and non-
adsorbed samples were then assayed at multiple 3-fold
dilutions for neutralizing activity against B.SS1196, C.TV-1,
C.DU123, C.DU172, C.02ZM233M, and A.92RW020 as
described above.
For immunization of guinea pigs with CON-S V3, we used
the CON-S V3 peptide (Table 7) and a second peptide, GTH1-
V3, that is comprised of HIV-1 gag p24 Th epitope (GTH1)
(YKRWIILGLNKIVRM) synthesized N-terminal to the CON-S
V3 (TRPNNNTRKSIHIGPGQAFYAT) for enhancement of
peptide immunogenicity.
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